Therapeutic Area | MeSH |
---|---|
urogenital diseases | D000091642 |
cardiovascular diseases | D002318 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
HYTRIN | Abbott Biotherapeutics | N-019057 DISCN | 1987-08-07 | 4 products |
HYTRIN | Abbott Biotherapeutics | N-020347 DISCN | 1994-12-14 | 4 products, RLD |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hypertension | EFO_0000537 | D006973 | I10 |
prostatic hyperplasia | EFO_0000284 | D011470 | N40 |
urinary retention | HP_0000016 | D016055 | R33 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | — | — | 2 | 7 | 9 |
Hypertension | D006973 | EFO_0000537 | I10 | — | — | 2 | 1 | 3 | 6 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | 1 | — | 2 |
Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | 1 | — | 1 | — | 2 |
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | 1 | — | 1 |
Hyperhidrosis | D006945 | HP_0000975 | — | — | — | — | 1 | — | 1 |
Gait analysis | D000077107 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 1 | — | — | 1 |
Hypercholesterolemia | D006937 | HP_0003124 | — | — | — | 1 | — | — | 1 |
Coronary disease | D003327 | — | — | — | — | 1 | — | — | 1 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | 1 | — | — | 1 |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | — | — | 1 |
Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Secondary parkinson disease | D010302 | EFO_1001175 | G21 | — | 2 | — | — | — | 2 |
Rem sleep behavior disorder | D020187 | EFO_0007462 | G47.52 | — | 2 | — | — | — | 2 |
Chronic renal insufficiency | D051436 | — | N18 | — | 1 | — | — | — | 1 |
Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | 1 | — | — | — | 1 |
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | — | 1 |
Dementia | D003704 | EFO_0003862 | F03 | 1 | 1 | — | — | — | 1 |
Carotid stenosis | D016893 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ejaculation | D004542 | — | — | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
Lower urinary tract symptoms | D059411 | EFO_0008008 | — | — | — | — | — | 1 | 1 |
Nocturia | D053158 | — | R35.1 | — | — | — | — | 1 | 1 |
Pheochromocytoma | D010673 | — | — | — | — | — | — | 1 | 1 |
Urinary retention | D016055 | HP_0000016 | R33 | — | — | — | — | 1 | 1 |
Drug common name | Terazosin |
INN | terazosin |
Description | Terazosin is a member of quinazolines, a member of piperazines, a member of furans and a primary amino compound. It has a role as an antineoplastic agent, an antihypertensive agent and an alpha-adrenergic antagonist. |
Classification | Small molecule |
Drug class | antihypertensives (prazosin type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC |
PDB | — |
CAS-ID | 63590-64-7 |
RxCUI | — |
ChEMBL ID | CHEMBL611 |
ChEBI ID | 9445 |
PubChem CID | 5401 |
DrugBank | DB01162 |
UNII ID | 8L5014XET7 (ChemIDplus, GSRS) |